List of Excipients in Branded Drug SOTYLIZE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	SOTYLIZE	sotalol hydrochloride	24338-530	CITRIC ACID MONOHYDRATE
Azurity Pharmaceuticals Inc	SOTYLIZE	sotalol hydrochloride	24338-530	SODIUM BENZOATE
Azurity Pharmaceuticals Inc	SOTYLIZE	sotalol hydrochloride	24338-530	SODIUM CITRATE
Azurity Pharmaceuticals Inc	SOTYLIZE	sotalol hydrochloride	24338-530	SUCRALOSE

SOTYLIZE Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

SOTYLIZE is a 5 mg/mL sotalol hydrochloride oral solution for patients who require liquid dosing. Its excipient system supports chemical stability, preservation, pH control, solubility, and dose measurement rather than creating a differentiated delivery platform. The strongest commercial opportunities are preservative-free pediatric formulations, unit-dose hospital packaging, improved palatability, enteral-tube compatibility, and authorized-generic or private-label supply.

SOTYLIZE was approved by the U.S. Food and Drug Administration through a drug application for an oral liquid presentation of an established antiarrhythmic. Because sotalol has long been marketed in tablet form, the product’s commercial value depends primarily on dosage-form convenience, dosing flexibility, supply reliability, and institutional use rather than molecular exclusivity.[1]

What is SOTYLIZE and how is it used?

SOTYLIZE contains sotalol hydrochloride at a concentration of 5 mg/mL. It is administered orally and is used for the treatment of life-threatening ventricular arrhythmias and for maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation or atrial flutter.[1]

The product has a boxed warning for proarrhythmia, including QT prolongation and torsades de pointes. Initiation or reinitiation generally requires an inpatient setting with continuous electrocardiographic monitoring and resuscitation capability because sotalol dosing depends on renal function, QT interval, heart rate, and clinical response.[1]

SOTYLIZE product profile

Attribute	SOTYLIZE profile
Active ingredient	Sotalol hydrochloride
Dosage form	Oral solution
Strength	5 mg/mL
Therapeutic class	Class III antiarrhythmic with beta-blocking activity
Primary users	Adult and pediatric patients requiring liquid dosing
FDA pathway	NDA-based approval for an oral solution
Key dosing variable	Renal function and QT response
Principal commercial advantage	Flexible liquid dosing where tablets are unsuitable
Principal clinical constraint	QT prolongation and inpatient initiation requirements

The 5 mg/mL concentration permits weight-based and renal-adjusted dosing without tablet splitting. It also supports pediatric dosing where commercially available tablet strengths may not provide adequate dose flexibility.

What excipients are used in SOTYLIZE?

The FDA-approved labeling identifies citric acid, edetate disodium, glycerin, methylparaben, propylene glycol, purified water, and sodium citrate among the inactive ingredients.[1]

Excipient functions

Excipient	Likely formulation role
Citric acid	Acidulant and pH adjustment
Sodium citrate	Buffering and pH control
Edetate disodium	Chelating agent that can reduce metal-catalyzed degradation
Glycerin	Co-solvent, humectant, viscosity modifier, and taste-masking aid
Propylene glycol	Co-solvent and solubilization aid
Methylparaben	Antimicrobial preservative
Purified water	Primary vehicle

The formulation uses a conventional multidimensional liquid-product strategy. The citrate system controls pH, edetate disodium limits the effect of trace metals, propylene glycol and glycerin support solubilization and mouthfeel, and methylparaben protects the multidose bottle against microbial growth.

The formulation’s commercial strength is its practical balance between stability and manufacturability. The same excipient architecture also creates opportunities for differentiated follow-on products because each component can be reconsidered for pediatric safety, sensory performance, packaging, or regulatory positioning.

What excipient risks affect SOTYLIZE commercialization?

The principal formulation risks are preservative exposure, propylene glycol exposure, taste, dosing accuracy, and packaging compatibility.

Methylparaben and pediatric positioning

Methylparaben allows multidose packaging, but preservatives can complicate pediatric positioning. Parents, pediatric specialists, and hospital formularies increasingly favor preservative-free products when repeated dosing is expected or when vulnerable populations are involved.

A preservative-free SOTYLIZE-equivalent would require a validated microbial-control strategy. Options could include unit-dose packaging, smaller short-use bottles, sterile manufacturing, or a validated in-use period supported by packaging and microbiological data. Removing methylparaben is not a simple substitution because the finished product must maintain chemical stability and microbiological quality throughout its labeled use period.

Propylene glycol exposure

Propylene glycol is widely used in oral liquids, but exposure can become relevant in neonates, young children, patients with renal impairment, or patients receiving multiple propylene glycol-containing medicines. The risk depends on dose, frequency, duration, and patient characteristics.

A low-propylene-glycol or propylene-glycol-free formulation could support pediatric and hospital differentiation. The technical challenge is maintaining sotalol solubility and product stability while avoiding a large increase in glycerin, ethanol, polyethylene glycol, surfactants, or other excipients with their own regulatory and tolerability issues.

Taste and adherence

Sotalol is not inherently associated with a consumer-friendly taste profile. Glycerin may improve mouthfeel, but the label does not establish that SOTYLIZE has a patented or clinically differentiated taste-masking system.

Flavor optimization is a realistic commercial opportunity. Potential approaches include berry or citrus flavors, sweetener systems, bitterness blockers, and packaging that minimizes odor and dosing exposure. Any new flavor system would need compatibility testing because pH, preservative performance, and assay stability can change after flavor addition.

Dose measurement

Liquid antiarrhythmic dosing creates a medication-error risk if caregivers use household spoons or confuse milligrams with milliliters. A calibrated oral syringe, clear dose markings, and pharmacy-level education are therefore commercially important. Packaging improvements may generate more defensible value than minor changes to the excipient list.

What formulations are protected by SOTYLIZE’s patent estate?

SOTYLIZE’s principal protection is likely to arise from regulatory status, product-specific formulation know-how, trademarks, manufacturing controls, and any listed patents rather than from broad active-ingredient composition claims. Sotalol itself is an established active pharmaceutical ingredient, and the tablet market predates SOTYLIZE by decades.

The FDA Orange Book is the controlling source for determining whether SOTYLIZE has listed patents, pediatric exclusivity, or other product-specific exclusivity. The FDA label identifies the approved product and inactive ingredients but does not, by itself, establish the complete Orange Book patent position.[1,2]

Patent and exclusivity assessment

Protection category	Relevance to SOTYLIZE
Active-ingredient patent	Unlikely to provide meaningful protection because sotalol is an old molecule
Formulation patent	Could protect concentration, pH, excipient combinations, stability, or preservative system if listed and enforceable
Method-of-use patent	Could cover a specific patient population or dosing method, subject to Orange Book listing rules
Trademark	SOTYLIZE brand protection can remain commercially relevant after generic entry
Regulatory exclusivity	May have applied at approval, but any original period would not substitute for long-term molecular exclusivity
Trade secrets	Manufacturing process, flavor system, packaging controls, and stability data may remain important
Pediatric exclusivity	Only relevant if separately awarded and listed by FDA

A potential generic sponsor would typically evaluate an Abbreviated New Drug Application route, product-specific guidance, formulation equivalence, inactive-ingredient permissibility, and any Orange Book-listed patents. Because SOTYLIZE is an oral solution, a generic applicant may have a more straightforward equivalence pathway than a modified-release or complex drug-device product, although formulation and stability requirements remain material.

When does SOTYLIZE lose exclusivity?

SOTYLIZE’s practical exclusivity depends on the combination of Orange Book patents, FDA regulatory exclusivity, and commercial barriers. The original approval occurred for an established active ingredient, so long-term exclusivity is more likely to depend on formulation and market execution than on new chemical entity protection.

A three-year period of exclusivity may be relevant to an approval supported by new clinical investigations, but the exact scope and expiration must be verified against FDA regulatory records for the application. Any remaining protection must be assessed separately from the age of the sotalol molecule.[2]

Generic entry scenarios

Scenario	Commercial effect
No blocking patent or exclusivity	ANDA entry could occur after FDA approval and commercial launch readiness
Formulation patent remains enforceable	Generic approval or launch could be delayed, depending on patent scope and litigation
Method-of-use patent only	Label carve-outs may permit narrower generic indications
Authorized generic launch	Brand owner or licensee could preserve channel presence while reducing third-party share
Limited market demand	Generic entry may be delayed by modest market size despite legal availability
Multiple liquid competitors	Price compression and pharmacy substitution would increase rapidly

Because sotalol tablets are already available in multiple strengths, generic manufacturers may focus first on tablet markets. The oral-solution segment is smaller but can attract competitors if pediatric demand, hospital utilization, or supply constraints support adequate margins.

What FDA and Orange Book issues affect generic SOTYLIZE?

A generic sotalol oral solution would need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. The applicant would also need to address inactive ingredients, concentration, pH, microbial quality, preservative effectiveness where applicable, container closure, and dose-delivery performance.

The most important regulatory distinction is that an ANDA product does not necessarily need to use the exact same inactive ingredients as the reference product. Differences may be acceptable if the formulation remains pharmaceutically equivalent, bioequivalent, safe, stable, and compliant with FDA requirements.

A formulation with different preservatives, flavors, sweeteners, or co-solvents could therefore compete with SOTYLIZE if the applicant resolves the relevant chemistry, microbiology, and labeling requirements.

Which commercial opportunities exist for SOTYLIZE excipients?

Preservative-free pediatric formulation

This is the clearest formulation opportunity. A preservative-free product could target infants, children, long-term users, and hospitals seeking to reduce exposure to methylparaben. Unit-dose cups or prefilled oral syringes could replace the multidose bottle and reduce microbial contamination risk.

Improved taste and adherence

A palatable formulation could improve caregiver acceptance and reduce dosing refusal. The opportunity is strongest in pediatric cardiology and chronic atrial arrhythmia management, where treatment may continue for extended periods.

Unit-dose and hospital packaging

Unit-dose packaging could improve medication safety in inpatient settings, particularly during initiation and dose titration. Packaging could include a calibrated oral syringe, barcoded dose information, and tamper-evident features.

Enteral-tube compatibility

A formulation specifically characterized for nasogastric and gastrostomy-tube administration could address a practical gap. Development would require testing for adsorption, dose recovery, clogging, dilution, tube material compatibility, and administration volume.

Lower excipient burden

A formulation with reduced propylene glycol, reduced preservative load, or fewer sensitizing excipients could create a differentiated pediatric and institutional profile. The product would need to preserve solubility and stability at the 5 mg/mL concentration.

Contract manufacturing and licensing

Sotalol oral solution could support licensing or contract-manufacturing arrangements involving:

• Hospital and specialty-pharmacy supply
• Private-label pediatric formulations
• Regional distribution rights
• Authorized-generic commercialization
• Packaging and oral-syringe partnerships
• Formulation technology licenses for preservative-free liquids

The most attractive partner would likely have liquid-dose manufacturing, pediatric regulatory experience, and access to hospital or specialty-pharmacy channels.

How strong is the SOTYLIZE patent estate?

The estate should be viewed as moderate at the product level and weak at the molecule level. Sotalol itself provides little meaningful long-term exclusivity because it is an established active ingredient. Product-level strength depends on whether SOTYLIZE has enforceable claims covering the specific 5 mg/mL oral solution, citrate buffer, preservative system, stability profile, packaging, or a defined patient population.

Trade-secret protection may be more important than patent protection for manufacturing controls, flavor selection, microbiological validation, and commercial packaging. These barriers can delay competitive replication but generally do not prevent FDA approval of a technically equivalent product.

What patent litigation and settlement issues affect SOTYLIZE?

The principal litigation risk would arise if an ANDA applicant files a Paragraph IV certification against an Orange Book-listed formulation or method-of-use patent. The brand owner could then bring infringement litigation within the statutory period, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]

No litigation or settlement terms are established by the FDA label alone. Any assessment of Paragraph IV challenges, launch dates, or settlement restrictions must be tied to current FDA Orange Book records and court filings for the relevant NDA and patents.

What is the revenue exposure and competitive landscape?

SOTYLIZE-specific revenue is not separately identified in the FDA label. Commercial exposure is concentrated in patients who cannot reliably use tablets, including children, patients requiring individualized dosing, patients with swallowing difficulty, and institutions that prefer a liquid product.

Competition comes from four directions:

1. Sotalol tablets and generic tablet strengths.
2. Extemporaneously compounded sotalol liquids.
3. Future generic oral solutions.
4. Alternative antiarrhythmic therapies, including amiodarone, dofetilide, and other agents selected according to patient-specific risk.

The product’s economic value is highest where compounded liquids create quality, availability, dosing, or documentation problems. A commercial strategy that reduces those weaknesses through stable supply, superior packaging, and a pediatric-friendly formulation would be more defensible than a strategy based solely on brand recognition.

Key Takeaways

• SOTYLIZE is a 5 mg/mL sotalol hydrochloride oral solution.
• Its excipient system uses citrate buffering, edetate disodium, glycerin, propylene glycol, methylparaben, and purified water.
• The primary formulation opportunities are preservative-free dosing, better taste, reduced propylene glycol exposure, unit-dose packaging, and enteral-tube compatibility.
• Sotalol’s old active-ingredient status limits molecule-level exclusivity.
• Commercial protection depends on formulation patents, regulatory exclusivity, trade secrets, packaging, and distribution.
• Generic risk is meaningful because an oral solution may be more accessible through an ANDA pathway than a complex drug-device product.
• The strongest target markets are pediatric cardiology, hospital pharmacies, specialty pharmacies, and patients unable to use tablets.
• An authorized generic or licensed private-label liquid could compete effectively if it preserves dose accuracy, stability, and supply reliability.

FAQs

Can SOTYLIZE be reformulated without methylparaben?

Yes, a reformulated product could use unit-dose packaging or another validated microbiological-control strategy. Removing methylparaben would require new stability, preservative-effectiveness, packaging, and regulatory support.

Is propylene glycol in SOTYLIZE a barrier to pediatric use?

Not necessarily. Pediatric use depends on total exposure, patient age, renal function, treatment duration, and concurrent medicines. A lower-propylene-glycol formulation could provide commercial differentiation.

Could a generic SOTYLIZE use different flavors?

Yes. A generic oral solution may use different flavoring or other inactive ingredients if FDA requirements for safety, pharmaceutical equivalence, bioequivalence, stability, and labeling are met.

Does SOTYLIZE have biosimilar risk?

No. SOTYLIZE is a small-molecule oral solution. Competitive products would generally be evaluated through generic-drug pathways rather than the biosimilar pathway.

What is the most valuable follow-on product concept?

A preservative-free, palatable, unit-dose sotalol oral solution with a calibrated oral syringe and validated enteral-tube compatibility would have the clearest differentiation potential.

References

1. U.S. Food and Drug Administration. (2024). SOTYLIZE (sotalol hydrochloride) oral solution prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations.
3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.